Antag Therapeutics

Laboratory research
#Antag Therapeutics #Clinical trial #Obesity

Novel obesity drug could be ‘combination partner of choice’ 

Biotechnology company Antag Therapeutics has revealed promising results from its novel GIPR antagonist for the treatment of obesity.  AT7687, a first-in-class GIPR antagonist, was trialled in a Phase I randomised, double-blind, placebo-controlled study. Results show AT7687 demonstrated a favourable safety and tolerability profile across all doses.  The… Read More

#News

Woman standing on scales
#Antag Therapeutics #Financing #Obesity #Weight loss

€80 million financing will advance GIPR drugs for obesity

Biopharmaceutical company Antag Therapeutics has announced the closing of an €80 million Series A financing.   The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of… Read More

#Business & Investment #News

#Antag Therapeutics #FDA #GLP-1 #Obesity #Phase I trial #Weight loss

FDA clears GIP receptor agonist trial in obese subjects

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Antag Therapeutics’ lead molecule AT-7687 for obesity. The company has announced plans to initiate a Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and… Read More

#News #Regulatory